NASDAQ: GENE - Genetic Technologies Limited

Rentabilidad a seis meses: -4.38%
Rendimiento de dividendos: 0.00%
Sector: Healthcare

Calendario de promoción Genetic Technologies Limited


Acerca de la empresa Genetic Technologies Limited

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

más detalles
It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

IPO date 2005-09-02
ISIN US37185R3075
Industry Life Sciences Tools & Services
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://genetype.com
Цена ао 0.765
Cambio de precio por día: 0% (0.765)
Cambio de precio por semana.: 0% (0.765)
Cambio de precio por mes: 0% (0.765)
Cambio de precio en 3 meses.: -0.6494% (0.77)
Cambio de precio en seis meses: -4.38% (0.8)
Cambio de precio por año: -71.67% (2.7001)
Cambio de precio en 3 años.: -58.2% (1.83)
Cambio de precio en 5 años.: -79.32% (3.7)
Cambio de precio en 10 años.: 0% (0.765)
Cambio de precio desde principios de año.: 0% (0.765)

Subestimación

Nombre Significado Calificación
P/S 44.57 1
P/BV 186.62 1
P/E 0 0
EV/EBITDA -29.87 0
Total: 1.75

Eficiencia

Nombre Significado Calificación
ROA, % -114.22 0
ROE, % -184.98 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.0766 10
Total: 9.6

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 77604.62 10
Rentabilidad Ebitda, % 87.88 9
Rentabilidad EPS, % 8989 10
Total: 9.2

Instituciones Volumen Compartir, %
Morgan Stanley 17289 0.45
Rhumbline Advisers 3739 0.1
UBS Group AG 2994 0.08
Wells Fargo & Company 130 0
SIMPLEX TRADING, LLC 18 0



Supervisor Título profesional Pago año de nacimiento
Mr. Simon Morriss Chief Executive Officer 262.57k
Mr. Carl S. Stubbings BSc Chief Commercial Officer 173.93k
Mr. Kevin Camilleri Chief Executive Officer of EasyDNA 167.85k
Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA Consultant 119.53k
Mr. Mark Ziirsen CFO & Company Secretary 1963 (62 año)
Dr. Erika Spaeth Ph.D. Director of Clinical & Scientific Affairs

DIRECCIÓN: Australia, Fitzroy, 60-66 Hanover Street - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://genetype.com